Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1995 Dec;72(6):1551–1555. doi: 10.1038/bjc.1995.546

Carboplatin combined with amifostine, a bone marrow protectant, in the treatment of non-small-cell lung cancer: a randomised phase II study.

D C Betticher 1, H Anderson 1, M Ranson 1, K Meely 1, W Oster 1, N Thatcher 1
PMCID: PMC2034079  PMID: 8519676

Abstract

Amifostine (WR-2721), a thiol compound, has been shown to protect normal tissue from alkylating agents and cisplatin-induced toxicity without loss of anti-tumour effects. To confirm this result, we conducted a phase II randomised trial to determine if the addition of amifostine reduces the toxicity of carboplatin without loss of anti-tumour activity in patients with inoperable non-small-cell lung cancer (NSCLC). After the first course of carboplatin (600 mg m-2 i.v. infusion), 21 patients were randomised to receive three cycles of carboplatin alone (C arm) or three infusions of amifostine at 910 mg m-2 (CA arm) at 28 day intervals. The amifostine was given 20 min before and at 2 and 4 h after carboplatin. Since the 910 mg m-2 amifostine infusion led to hypotension in six patients, the dosage was reduced by 25%, to 683 mg m-2 t.i.d., in the other four patients. Amifostine was well tolerated at this dose level. Five patients in the CA arm and three in the C arm had their planned treatment discontinued owing to progressive disease (n = 3), amifostine side-effects (hypotension, sneezing and sickness, n = 4), and carboplatin-induced thrombocytopenia (n = 1). Bone marrow and renal function at study entry and after the first course of carboplatin before randomisation were similar in both treatment arms. Twenty courses of carboplatin+amifostine have been compared with 25 courses of carboplatin alone. Although there was no statistically significant difference with respect to haematological values comparing both arms, the median time to platelet recovery (> 100 x 10(9) l-1) (13.5 days vs 21 days; P = 0.04) and the need for hospitalisation for i.v. antibiotic and other supportive treatment tended to be reduced in the CA arm (0/20 vs 6/25 patient courses; P = 0.06). Response rates and median survival (14 vs 9 months) were no different, excluding tumour protection activity by amifostine. These results with a small number of patients suggest that amifostine given with carboplatin may reduce the duration of thrombocytopenia and hospitalisation.

Full text

PDF
1551

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Budd G. T., Ganapathi R., Bauer L., Murthy S., Adelstein D., Weick J., Gibson V., McLain D., Sergi J., Bukowski R. M. Phase I study of WR-2721 and carboplatin. Eur J Cancer. 1993;29A(8):1122–1127. doi: 10.1016/s0959-8049(05)80301-6. [DOI] [PubMed] [Google Scholar]
  2. Calvert A. H., Newell D. R., Gumbrell L. A., O'Reilly S., Burnell M., Boxall F. E., Siddik Z. H., Judson I. R., Gore M. E., Wiltshaw E. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol. 1989 Nov;7(11):1748–1756. doi: 10.1200/JCO.1989.7.11.1748. [DOI] [PubMed] [Google Scholar]
  3. Canetta R., Rozencweig M., Carter S. K. Carboplatin: the clinical spectrum to date. Cancer Treat Rev. 1985 Sep;12 (Suppl A):125–136. doi: 10.1016/0305-7372(85)90027-1. [DOI] [PubMed] [Google Scholar]
  4. Capizzi R. L. Protection of normal tissues from the cytotoxic effects of chemotherapy by amifostine (Ethyol): clinical experiences. Semin Oncol. 1994 Oct;21(5 Suppl 11):8–15. [PubMed] [Google Scholar]
  5. Capizzi R. L., Scheffler B. J., Schein P. S. Amifostine-mediated protection of normal bone marrow from cytotoxic chemotherapy. Cancer. 1993 Dec 1;72(11 Suppl):3495–3501. doi: 10.1002/1097-0142(19931201)72:11+<3495::aid-cncr2820721617>3.0.co;2-b. [DOI] [PubMed] [Google Scholar]
  6. Gandara D. R., Perez E. A., Weibe V., De Gregorio M. W. Cisplatin chemoprotection and rescue: pharmacologic modulation of toxicity. Semin Oncol. 1991 Feb;18(1 Suppl 3):49–55. [PubMed] [Google Scholar]
  7. Gandara D. R., Wiebe V. J., Perez E. A., Makuch R. W., DeGregorio M. W. Cisplatin rescue therapy: experience with sodium thiosulfate, WR2721, and diethyldithiocarbamate. Crit Rev Oncol Hematol. 1990;10(4):353–365. doi: 10.1016/1040-8428(90)90010-p. [DOI] [PubMed] [Google Scholar]
  8. Glover D., Glick J. H., Weiler C., Fox K., Guerry D. WR-2721 and high-dose cisplatin: an active combination in the treatment of metastatic melanoma. J Clin Oncol. 1987 Apr;5(4):574–578. doi: 10.1200/JCO.1987.5.4.574. [DOI] [PubMed] [Google Scholar]
  9. Glover D., Glick J. H., Weiler C., Hurowitz S., Kligerman M. M. WR-2721 protects against the hematologic toxicity of cyclophosphamide: a controlled phase II trial. J Clin Oncol. 1986 Apr;4(4):584–588. doi: 10.1200/JCO.1986.4.4.584. [DOI] [PubMed] [Google Scholar]
  10. McCulloch W., Scheffler B. J., Schein P. S. New protective agents for bone marrow in cancer therapy. Cancer Invest. 1991;9(3):279–287. doi: 10.3109/07357909109021325. [DOI] [PubMed] [Google Scholar]
  11. Mollman J. E., Glover D. J., Hogan W. M., Furman R. E. Cisplatin neuropathy. Risk factors, prognosis, and protection by WR-2721. Cancer. 1988 Jun 1;61(11):2192–2195. doi: 10.1002/1097-0142(19880601)61:11<2192::aid-cncr2820611110>3.0.co;2-a. [DOI] [PubMed] [Google Scholar]
  12. O'Rourke N., McCloskey E., Kanis J. WR-2721 and hypocalcemia. J Clin Oncol. 1994 Jan;12(1):232–232. doi: 10.1200/JCO.1994.12.1.232. [DOI] [PubMed] [Google Scholar]
  13. Patchen M. L., MacVittie T. J., Souza L. M. Postirradiation treatment with granulocyte colony-stimulating factor and preirradiation WR-2721 administration synergize to enhance hemopoietic reconstitution and increase survival. Int J Radiat Oncol Biol Phys. 1992;22(4):773–779. doi: 10.1016/0360-3016(92)90522-j. [DOI] [PubMed] [Google Scholar]
  14. Poplin E. A., LoRusso P., Lokich J. J., Gullo J. J., Leming P. D., Schulz J. J., Veach S. R., McCulloch W., Baker L., Schein P. Randomized clinical trial of mitomycin-C with or without pretreatment with WR-2721 in patients with advanced colorectal cancer. Cancer Chemother Pharmacol. 1994;33(5):415–419. doi: 10.1007/BF00686271. [DOI] [PubMed] [Google Scholar]
  15. Schuchter L. M., Luginbuhl W. E., Meropol N. J. The current status of toxicity protectants in cancer therapy. Semin Oncol. 1992 Dec;19(6):742–751. [PubMed] [Google Scholar]
  16. Shaw L. M., Turrisi A. T., Glover D. J., Bonner H. S., Norfleet A. L., Weiler C., Kligerman M. M. Human pharmacokinetics of WR-2721. Int J Radiat Oncol Biol Phys. 1986 Aug;12(8):1501–1504. doi: 10.1016/0360-3016(86)90203-8. [DOI] [PubMed] [Google Scholar]
  17. Treskes M., Boven E., van de Loosdrecht A. A., Wijffels J. F., Cloos J., Peters G. J., Pinedo H. M., van der Vijgh W. J. Effects of the modulating agent WR2721 on myelotoxicity and antitumour activity in carboplatin-treated mice. Eur J Cancer. 1994;30A(2):183–187. doi: 10.1016/0959-8049(94)90084-1. [DOI] [PubMed] [Google Scholar]
  18. Treskes M., Holwerda U., Klein I., Pinedo H. M., van der Vijgh W. J. The chemical reactivity of the modulating agent WR2721 (ethiofos) and its main metabolites with the antitumor agents cisplatin and carboplatin. Biochem Pharmacol. 1991 Nov 6;42(11):2125–2130. doi: 10.1016/0006-2952(91)90347-8. [DOI] [PubMed] [Google Scholar]
  19. Treskes M., van der Vijgh W. J. WR2721 as a modulator of cisplatin- and carboplatin-induced side effects in comparison with other chemoprotective agents: a molecular approach. Cancer Chemother Pharmacol. 1993;33(2):93–106. doi: 10.1007/BF00685326. [DOI] [PubMed] [Google Scholar]
  20. Wadler S., Haynes H., Beitler J. J., Goldberg G., Holland J. F., Hochster H., Bruckner H., Mandeli J., Smith H., Runowicz C. Management of hypocalcemic effects of WR2721 administered on a daily times five schedule with cisplatin and radiation therapy. The New York Gynecologic Oncology Group. J Clin Oncol. 1993 Aug;11(8):1517–1522. doi: 10.1200/JCO.1993.11.8.1517. [DOI] [PubMed] [Google Scholar]
  21. Yuhas J. M., Spellman J. M., Jordan S. W., Pardini M. C., Afzal S. M., Culo F. Treatment of tumours with the combination of WR-2721 and cis-dichlorodiammineplatinum (II) or cyclophosphamide. Br J Cancer. 1980 Oct;42(4):574–585. doi: 10.1038/bjc.1980.282. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. van Laar J. A., van der Wilt C. L., Treskes M., van der Vijgh W. J., Peters G. J. Effect of WR-2721 on the toxicity and antitumor activity of the combination of carboplatin and 5-fluorouracil. Cancer Chemother Pharmacol. 1992;31(2):97–102. doi: 10.1007/BF00685094. [DOI] [PubMed] [Google Scholar]
  23. van der Wilt C. L., van Laar J. A., Gyergyay F., Smid K., Peters G. J. Biochemical modification of the toxicity and the anti-tumour effect of 5-fluorouracil and cis-platinum by WR-2721 in mice. Eur J Cancer. 1992;28A(12):2017–2024. doi: 10.1016/0959-8049(92)90251-v. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES